Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Sep 28, 2026
TickeronGET DAILY SIGNALS
Church & Dwight (CHD) vs Clorox (CLX): Diverging Paths in Consumer Staples

Church & Dwight (CHD) vs Clorox (CLX): Diverging Paths in Consumer Staples

Key Takeaways

  • Church & Dwight (CHD) is gaining market share on volume-led organic sales growth, while Clorox (CLX) is working through an ERP (enterprise resource planning) transition that is temporarily distorting its results.
  • CHD trades at a premium valuation with modest dividend yield, whereas CLX screens as a cheaper, higher-yielding stock with a steeper recent drawdown.
  • Relative performance has diverged sharply: CHD is positive year to date, while CLX has underperformed the broader consumer staples sector.
  • Both companies face inflation, tariff, and promotional-cost pressures, but their near-term catalysts and momentum profiles point in different directions.

Setting the Stage for These Two Staples Names

Church & Dwight and Clorox are two well-known names in the household and personal care products industry, but they occupy meaningfully different positions in the current market. This stock comparison is useful for investors and traders evaluating how two consumer staples businesses with distinct growth profiles, valuation multiples, and risk factors stack up against one another. While both operate in defensive categories such as cleaning, laundry, and health products, their recent momentum, market positioning, and sentiment have diverged. The analysis below reviews each company's business context, recent relative performance, and the factors currently shaping investor expectations. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in the industry.

Church & Dwight Overview and Recent Performance

CHD, or Church & Dwight Co., Inc., is the leading U.S. producer of baking soda and owns brands including Arm & Hammer, OxiClean, TheraBreath, Hero, Batiste, and Touchland. The company derives roughly 80% of its sales from the U.S. and has been reshaping its portfolio by exiting slower-growing businesses, such as its vitamin brands, while acquiring faster-growing assets including hand-sanitizer maker Touchland and stain-removal brand Miss Mouth's Messy Eater.

In recent market activity, CHD has shown resilience but has not been immune to selling pressure. The stock delivered positive year-to-date gains, supported by strong quarterly results that featured organic sales growth well above management's initial guidance, driven by volume. However, in recent weeks the shares pulled back from their highs amid a broader pause in momentum. Analysts have cited a premium valuation—roughly 26 times forward earnings—as a key consideration, even as the company's gross margin expansion and 30th consecutive annual dividend increase underscore its financial discipline. From what I see, the company’s consistent execution stands out here.

Clorox Overview and Recent Performance

CLX, or The Clorox Company, manufactures cleaning, disinfecting, food, and personal care products under brands such as Clorox, Pine-Sol, Glad, Fresh Step, Hidden Valley, Brita, and Burt's Bees. The company recently completed the final phase of its U.S. ERP (enterprise resource planning) system rollout and closed its acquisition of GOJO Industries, owner of the Purell hand-sanitizer brand.

Clorox's recent stock behavior has been notably weak. The shares have fallen sharply over recent months and trade below their 50-day and 200-day moving averages. Much of the decline reflects transitory factors: retailers drew down inventory that had been built up ahead of the ERP transition, weighing on reported sales and earnings, and the company issued a voluntary product recall during the period. The stock now offers a dividend yield near 6%, reflecting both a higher payout and a lower share price. Analysts hold a predominantly "Hold" consensus rating as the market weighs these short-term disruptions against the company's longer-term transformation efforts. I’m watching this closely as the ERP issues work through the system.

Head-to-Head Comparison

The two companies diverge most clearly on growth trajectory and valuation. CHD is oriented around volume-led organic growth, premiumization, and disciplined acquisitions in faster-moving categories such as oral care and acne treatment. Its shares command a higher earnings multiple—reflecting that growth expectation—but pay a comparatively small dividend. CLX, by contrast, is a more mature, cash-generative business whose near-term results are distorted by the ERP transition and inventory drawdown. It trades at a lower earnings multiple and carries a much higher dividend yield, though the elevated payout has at times absorbed nearly all of its free cash flow.

Risk profiles also differ. CLX faces balance-sheet leverage and tighter dividend coverage following its GOJO acquisition, along with concentrated exposure to categories showing soft demand. CHD's main risks center on premium valuation, rising marketing costs, and competitive pressure from private-label brands. In terms of market sentiment, CHD has held up better despite a recent pullback, while CLX's technical posture remains bearish relative to the staples sector.

Tickeron AI Verdict

Based on observable factors, Tickeron's AI would currently lean toward CHD. The company's relative strength lies in more consistent trend behavior, volume-led organic growth, expanding margins, and a steadier earnings trajectory. CLX, while inexpensive on a valuation basis and offering a compelling dividend yield, is contending with transitory operational disruptions, weaker relative momentum, and higher balance-sheet risk. This assessment is probabilistic rather than definitive: it reflects current momentum, stability, and positioning, and could shift as Clorox's ERP-related headwinds fade and its GOJO integration matures.

Exploring AI-Assisted Trading Approaches

In my own analysis process, I sometimes look at Tickeron’s AI Trading Bots to see how automated strategies align with names like these. The platform’s Trending AI Robots section highlights bots whose performance and risk parameters fit current market conditions, offering a range of styles from short-term swings to longer-term trends. It’s one way to cross-check ideas without replacing core fundamental work.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CLX, CHD

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


CLX in downward trend: price expected to drop as it breaks its higher Bollinger Band on October 29, 2026

CLX broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 32 similar instances where the stock broke above the upper band. In 24 of the 32 cases the stock fell afterwards. This puts the odds of success at 75%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CLX's RSI Indicator exited the oversold zone, 17 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 49%.

The Momentum Indicator moved above the 0 level on October 08, 2026. You may want to consider a long position or call options on CLX as a result. In 48 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 49%.

The Moving Average Convergence Divergence (MACD) for CLX just turned positive on October 05, 2026. Looking at past instances where CLX's MACD turned positive, the stock continued to rise in 22 of 47 cases over the following month. The odds of a continued upward trend are 47%.

CLX moved above its 50-day moving average on October 29, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +2.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLX advanced for three days, in 180 of 319 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.

The Aroon Indicator entered an Uptrend today. In 75 of 193 cases where CLX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 39%.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 10 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 38 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. CLX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CLX's P/B Ratio (118.244) is slightly higher than the industry average of (20.608). P/E Ratio (18.257) is within average values for comparable stocks, (17.011). Projected Growth (PEG Ratio) (1.019) is also within normal values, averaging (1.518). Dividend Yield (0.057) settles around the average of (0.033) among similar stocks. P/S Ratio (1.542) is also within normal values, averaging (1.902).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.

Notable companies

The most notable companies in this group are Procter & Gamble Company (NYSE:PG), Colgate-Palmolive Company (NYSE:CL).

Industry description

Household/Personal Care companies sell products for home cleaning and/or personal hygiene and grooming purposes. Products of this industry include detergents, shampoos, soaps, cosmetics, fabric conditioners and infant care fragrances. Procter & Gamble, Unilever, Estee Lauder and Colgate-Palmolive are some of the biggest names in the business. A lot of the products become a necessary part of people’s daily routine, and therefore the industry is relatively less vulnerable to macroeconomic downturns. At the same time, product quality, consumer safety, and ease of use are extremely critical factors for a company to survive competition and earn recognition in this industry.

Market Cap

The average market capitalization across the Household/Personal Care Industry is 24.64B. The market cap for tickers in the group ranges from 60.48K to 375.27B. PG holds the highest valuation in this group at 375.27B. The lowest valued company is EOSS at 60.48K.

High and low price notable news

The average weekly price growth across all stocks in the Household/Personal Care Industry was -0%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was 8%. SLSN experienced the highest price growth at 6%, while TANH experienced the biggest fall at -32%.

Volume

The average weekly volume growth across all stocks in the Household/Personal Care Industry was 151%. For the same stocks of the Industry, the average monthly volume growth was 96% and the average quarterly volume growth was 34%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 51
Price Growth Rating: 51
SMR Rating: 73
Profit Risk Rating: 87
Seasonality Score: 19 (-100 ... +100)
View a ticker or compare two or three
CLX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a maker of detergent and cleaning products

Industry HouseholdPersonalCare

Industry
Household Or Personal Care
Address
1221 Broadway
Phone
+1 510 271-7000
Employees
7600
Web
https://www.thecloroxcompany.com
Interact to see
Advertisement
The Bitwise Solana Staking ETF (BSOL) advanced roughly 18% over the trailing 30 days, closely tracking a sharp rally in Solana (SOL). The move extends a broader recovery, with BSOL up approximately 77% over the past three months from its mid-2026 trough.
MSTY is an actively managed single-stock option income ETF (exchange-traded fund) that writes call options on Strategy (MSTR), formerly MicroStrategy, to generate current income. The portfolio is anchored by U.S. Treasury bills and MSTR option contracts rather than a diversified basket of equities, concentrating exposure in one volatile underlying.
AMDL has surged roughly +64% over the past 30 days, from about $47.59 to $78.10, mirroring a powerful rally in its sole underlying stock, AMD . The fund is a leveraged single-stock ETF (exchange-traded fund) designed to deliver 2x the daily return of AMD, amplifying both gains and losses.
AstraZeneca reported Q1 2026 total revenue of $15.3 billion, up 8% at constant exchange rates (CER, adjusting for currency fluctuations), beating consensus estimates around $14.8 billion. Core earnings per share (EPS) rose 5% to $2.58 at CER, amid a 12% increase in core operating profit.
Consensus estimates call for Q3 FY2026 revenue of approximately $3.37 billion, in line with the company's guidance midpoint of $3.35 billion. Non-GAAP earnings per share (EPS) expected at $9.16, edging above the guided midpoint of $9.08.
Church & Dwight (CHD) vs Clorox (CLX): Diverging Paths in Consumer Staples